이제중 > 교수진

본문 바로가기
연구 세계적 의생명과학 연구를 선도하는 연구자 양성

교수진 세계적 의생명과학 연구를 선도하는 연구자 양성

  • HOME
  • 연구
  • 교수진
교수진
교수진

본문

이제중
교실(과) 혈액종양내과학
연구(전공)분야 조혈모세포이식, 악성림프종, 다발골수종
이메일 drjejung@chonnam.ac.kr
홈페이지

학력

  • 1989. 전남대학교 의과대학 졸업 (의학사)
  • 1995. 전남대학교 대학원 의학과 (의학석사)
  • 1999. 전남대학교 대학원 의학과 (의학박사)

경력 및 해외 연수

  • <경력>
  • 1993.3–1997.2: 전남대학교병원, 내과전공의
  • 1997.3-1999.4: 전남대학교병원, 혈액종양내과 전임의
  • 1999.5–2001.5: 전남대학교병원, 혈액종양내과 임상전임강사
  • 2001.5–2003.7: 전남대학교병원, 혈액종양내과 임상조교수
  • 2003.7–2008.3: 전남대학교 의과대학, 혈액종양내과 조교수
  • 2008.4–2013.4: 전남대학교 의과대학, 혈액종양내과 부교수
  • 2010.3-2013.2: 전남대학교, 암면역치료연구특성화사업단 단장
  • 2011.3-2012.12: 화순전남대학교병원, 임상의학연구소 소장
  • 2013.1-2013.12: 화순전남대학교병원 의생명연구원 원장
  • 2011.3-현재: 화순전남대학교병원, 조혈모세포이식센터 소장
  • 2013.5-현재: 전남대학교 의과대학, 혈액종양내과 교수
  • <해외연수>
  • 2000.7-2001.1: 일본 동경 국립암센터병원, 조혈모세포이식센터 연수
  • 2006.2–2007.12: 미국 피츠버그대학 암연구소, 암면역치료그룹 연수

연구소개

 

수상경력

  • 1993: 전남대학교병원 인턴 병아리상
  • 1997: 전남대학교병원 최우수 전공의상
  • 2002: 한국과학기술단체총연합회 과학기술우수논문상
  • 2012: 대한 암학회 한국암연구재단 학술상
  • 2012: 한국과학기술단체총연합회 과학기술우수논문상

연구업적 및 저서

  • <연구업적>
  • [2014]
  • - Hong CY, Kim SY, Lee HJ, Lee SE, Lim SC, Rhee JH, Lee JJ. A bacterial flagellin in combination with proinflammatory cytokines activates human monocyte-derived dendritic cells to generate cytotoxic T lymphocytes having increased homing signals to cancer. J Immunother. 2014 Jan;37(1):16-25
  • - Hong CY, Lee HJ, Kim HJ, Lee JJ. The lymphoid chemokine CCL21 enhances the cytotoxic T lymphocyte-inducing functions of dendritic cells. Scand J Immunol.2014 Mar;79(3):173-80
  • - Jung SH, Lee YK, Lee HJ, Choi NR, Vo MC, Hoang MD, Lim MS, Nguyen-Pham TN, Kim HJ, Lee JJ. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro. Exp Hematol. 2014 Jan 6. pii: S0301-472X(14)00004-6. doi: 10.1016/j.exphem.2013.12.008.
  • - Jung SH, Yang DH, Ahn JS, Lee SS, Ahn SY, Kim YK, Kim HJ, Lee JJ. Decreased body mass index is associated with poor prognosis in patients with multiple myeloma. Ann Hematol. 2013 Dec 6.
  • [2013]
  • - Ahn JS, Yang DH, Jung SH, Chae YS, Sohn SK, Yhim HY, Kwak JY, Lee SR, Kim YK, Kim HJ, LeeJJ. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial. Ann Hematol. 2013;92(6):789-97.
  • - Hwang EC, Lim MS, Im CM, Kwon DD, Lee HJ, Nguyen-Pham TN, Lee YK, LeeJJ. Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells. Scand J Immunol. 2013;77(2):117-24.
  • - Jung SH, Bae SY, Ahn JS, Kang SJ, Yang DH, Kim YK, Kim HJ, LeeJJ. Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens. Int J Hematol. 2013;97(3):382-7.
  • - Jung SH, Park H, Ahn JS, Yang DH, Kim MY, Kim YK, Kim HJ, LeeJJ. Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen. Int J Hematol. 2013;97(1):92-7.
  • - Ahn JS, Rew SY, Yang DH, Jung SH, Kang SJ, Kim MY, Lee SS, Kim YK, Kim HJ, LeeJJ. Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma. Blood Res. 2013;48(1):35-9.
  • - Yang DH, Ahn JS, Byun BH, Min JJ, Kweon SS, Chae YS, Sohn SK, Lee SW, Kim HW, Jung SH, Kim YK, Kim HJ, Bom HS, LeeJJ. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Ann Hematol. 2013;92(4):471-9.
  • - Ahn JS, Yang DH, Duk Choi Y, Jung SH, Yhim HY, Kwak JY, Sung Park H, Shin MG, Kim YK, Kim HJ, LeeJJ. Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy. Am J Hematol. 2013 Sep;88(9):774-9
  • [2012]
  • - Nguyen-Pham TN, Yang DH, Nguyen TA, Lim MS, Hong CY, Kim MH, Lee HJ, Lee YK, Cho D, Bae SY, Ahn JS, Kim YK, Chung IJ, Kim HJ, Lee JJ. Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy. Cell Mol Immunol. 2012 Jan;9(1):45-53. doi: 10.1038/cmi.2011.23. -
  • - Lee HJ, Hong CY, Jin CJ, Kim MH, Lee YK, Nguyen-Pham TN, Lee H, Park BC, Chung IJ, Kim HJ, Lee JJ. Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer. Cell Mol Immunol. 2012 Mar;9(2):175-83.
  • - Lee HJ, Hong CY, Kim MH, Lee YK, Nguyen-Pham TN, Park BC, Yang DH, Chung IJ, Kim HJ, Lee JJ. In vitro induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential target for colorectal cancer. Exp Mol Med. 2012 Jan 31;44(1):60-7.
  • - Yang DH, Kim WS, Kim SJ, Kim JS, Kwak JY, Chung JS, Oh SY, Suh CW, Lee JJ. Pilot trial of yttrium-90 ((90)Y)-ibritumomab tiuxetan consolidation following R-CHOP chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53(5):807-11.
  • - Ahn JS, Yang DH, Jung SH, Park HC, Moon JH, Sohn SK, Bae SY, Kim YK, Kim HJ, Lee JJ. A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma. Ann Hematol. 2012;91:1023-30.
  • - Nguyen-Pham TN, Lee YK, Kim HJ, Lee JJ. Immunotherapy using Dendritic Cells against Multiple Myeloma: How to improve? Clin Dev Immunol. 2012;2012:397648.
  • [2011]
  • - Kim SJ, Kim K, Do YR, Bae SH, Yang DH, Lee JJ. Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Jpn J Clin Oncol. 2011 Mar;41(3):353-7.
  • - Park MH, Yang DH, Kim MH, Jang YY, Jang JH, Yoon JH, Lee JJ. Alpha-type 1 polarized dendritic cells loaded with apoptotic allogeneic breast cancer cells can induce potent cytotoxic T lymphocytes against breast cancer. Cancer Res Treat. 2011 Mar;43(1):56-66.
  • - Yang DH, Min JJ, Song HC, Jeong YY, Chung WK, Bae SY, Ahn JS, Kim YK, Bom HS, Chung IJ, Kim HJ, Lee JJ. Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer. 2011 Jun;47(9):1312-8.
  • - Nguyen-Pham TN, Im MS, Nguyen Thi TA, Lee YK, Jin CJ, Lee HJ, Hong CY, Ahn JS, Yang DH, Kim YK, Chung IJ, Park BC, Kim HJ and Lee JJ. Type I and II interferons enhance dendritic cell maturation and migrating capacity by regulation of CD38 and CD74 with synergistic effects of TLR agonists. Cell Mol Immunol. 2011 Jul;8(4):341-7.
  • - Yang DH, Kim MH, Lee YK, Hong CY, Lee HJ, Nguyen-Pham TN, Bae SY, Ahn JS, Kim YK, Chung IJ, Kim HJ, Kalinski P, Lee JJ. Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins. Ann Hematol. 2011 Dec;90(12):1419-26.
  • - Nguyen-Pham TH, Im CM, Nguyen Thi TA, Lim MS, Hong CY, Kim MH, Lee HJ, Lee YK, Ahn JS, Yang DH, Kim YK, Chung IJ, Kim HJ, Lee JJ. Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma. Leuk Res. 2011 Sep;35(9):1241-7.
  • [2010]
  • - Yang DH, Kim YK, Sohn SK, Jung JS, Joo YD, Lee JH, Lee J, Ahn JS, Moon JH, Shin HJ, Choi YJ, Lee WS, Kim HJ, Lee JJ. Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study. Clin Lymphoma Myeloma Leuk. 2010;10(1):62-7.
  • - Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, Kim HJ, Lee JJ. Clinical Efficacy of a Bortezomib, Cyclophosphamide, Thalidomide, and Dexamethasone (Vel-CTD) Regimen in Patients with Relapsed or Refractory Multiple Myeloma: A Phase II Study. Ann Hematol. 2010;89(5):475-82
  • - Jin CJ, Hong CY, Takei M, Chung SY, Park JS, Nguyen Pham TN, Choi SJN, Nam JH, Chung IJ, Kim HJ, Lee JJ. All-trans retinoic acid inhibits the differentiation, maturation, and function of human monocyte-derived dendritic cells. Leuk Res. 2010;34(4):513-20.
  • - Yang DH, Kim MH, Hong CY, Lee YK, Ahn JS, Bae WK, Kim YK, Chung IJ, Kim HJ, Kalinski P, Lee JJ. Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. Ann Hematol. 2010;89(8):795-801
  • - Pham TN, Hong CY, Min JJ, Rhee JH, Nguyen TA, Park BC, Yang DH, Park YK, Kim HR, Chung IJ, Kim HJ, Lee JJ. Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of toll-like receptor agonist. Exp Mol Med. 2010;42(6):407-19.
  • - Jung TY, Pham TN, Umeyama A, Shoji N, Hashimoto T, Lee JJ, Takei M. Ursolic acid isolated from Uncaria rhynchophylla activates human dendritic cells via TLR2 and/or TLR4 and induces the production of IFN-gamma by CD4+ naïve T cells. Eur J Pharmacol. 2010;643(2-3):297-303.
  • - Ahn JS, Rew SY, Shin MG, Kim HR, Yang DH, Cho D, Kim SH, Bae SY, Lee SR, Kim YK, Kim HJ, Lee JJ. Clinical significance of clonality and Epstein-Barr virus infection in adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2010;85(9):719-22
  • - Bae WK, Umeyama A, Chung IJ, Lee JJ, Takei M. Uncarinic acid C plus IFN-γ generates monocyte-derived dendritic cells and induces a potent Th1 polarization with capacity to migrate. Cell Immunol. 2010;266(1):104-10
  • [2009]
  • - Kim SK, Nguyen Pham TN, Nguyen Hoang TM, Kang HK, Jin CJ, Nam JH, Chung SY, Choi SJ, Yang DH, Kim YK, Chung IJ, Kim HJ, Lee JJ. Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens. Ann Hematol. 2009 Nov;88(11):1113-23.
  • - Yang DH, Park JS, Jin CJ, Kang HK, Nam JH, Rhee JH, Kim YK, Chung SY, Choi SJN, Kim HJ, Chung IJ, Lee JJ. The Dysfunction and Abnormal Signaling Pathway of Dendritic Cells Loaded by tumor Antigen can be Overcome by Neutralizing VEGF in Multiple Myeloma. Leuk Res 2009 May;33(5):665-70.
  • - Yang DH, Min JJ, Jeong YY, Ahn JS, Kim YK, Cho SH, Chung IJ, Bom HS, Kim HJ, Lee JJ. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma. Ann Hematol. 2009 May;88(5):425-32.
  • [2008]
  • - Lee JJ, Choi BH, Kang HK, Kim SK, Nam JH, Yang DH, Kim YK, Kim HJ, Chung IJ. Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients. Leuk Res. 2008 Nov;32(11):1653-60.
  • - Lee JJ, Kenneth Foon, Robbie Mailliard, Ravikumar Muthuswamy, and Pawel Kalinski. Type-1 polarized dendritic cells loaded with autologous tumor are potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol. 2008 Jul;84(1):319-25. Epub 2008 Apr 21.
  • - Park JS, Koh YS, Bang JY, Jeong YI, Lee JJ. Antitumor effect of all-trans retinoic acid-encapsulated nanoparticles of methoxy poly(ethylene glycol)-conjugated chitosan against CT-26 colon carcinoma in vitro. J Pharm Sci. 2008 Sep;97(9):4011-9.
  • [2007]
  • - Lee JJ, Choi BH, Kang HK, Park MS, Park JS, Kim SK, Nguyen Pham TN, Cho D, Nam JH, Kim YJ, Rhee JH, Yang DH, Kim YK, Kim HJ, Chung IJ. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leuk Lymphoma. 2007 Oct;48(10):2022-31.
  • - Lee JJ, Kim DH, Lee NY, Sohn SK, Kim JG, Kim HJ, Do YR, Park YH. Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. Br J Haematol. 2007 May;137(4):329-36.
  • [2006]
  • - Choi BH, Kang HK, Park JS, Kim SK, Pham TN, Zhu XW, Cho D, Nam JH, Chung IJ, Kim YJ, Rhee JH, Kim HJ, Lee JJ. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy. J Clin Apher. 2006 Dec;21(4):233-40.
  • - Kang HK, Park JS, Kim SK, Choi BH, Nguyen Pham TN, Zhu XW, Cho D, Nam JH, Kim YJ, Rhee JH, Chung IJ, Kim HJ, Lee JJ: Down-regulation of cellular VEGF levels induces differentiation of leukemic cells to functional leukemic-dendritic cells in acute myeloid leukemia. Leuk Lymphoma. 2006 Oct;47(10):2224-33.
  • - Lee JJ, Park MS, Park JS, Kang HK, Kim SK, Nguyen Pham TN, Zhu XW, Cho D, Nam JH, Kim YJ, Rhee JH, Chung IJ, Kim HJ. Induction of leukemic-cell-specific cytotoxic T lymphocytes by autologous monocyte-derived dendritic cells presenting leukemic cell antigens. J Clin Apher. 2006 Oct;21(3):188-94.
  • [2004]
  • - Lee JJ, Nam CE, Nam JH, Lee HC, Chung IJ, Park MS, Choi BH, Song WH, Lee IK, Park KS, Kook H, Hwang TJ, Takei M, Takaue Y, Kim HJ: Generation of cytotoxic donor CD8+ T cells against relapsing leukemic cells following allogeneic transplantation by the stimulation with leukemic cell- or leukemic lysate pulsed donor cell-derived dendritic cells. Leukemia Research 28(5): 517-524, 2004
  • - Lee JJ, Kim YK, Cho SH, Park KS, Chung IJ, Cho D, Ryang DW, Kim HJ: Hemolytic anemia as a sequela of arsenic intoxication following long-term ingestion of traditional Chinese medicine. Journal of Korean Medical Science 19(1):127-129, 2004
  • - Lee JJ, Song HC, Chung IJ, Bom HS, Cho D, Kim HJ: Clinical Efficacy and Prediction of response to granulocyte transfusion therapy from G-CSF and dexamethasone-stimulated donors into patients with neutropenia-related infections. Haematologica 89(5): 632-633, 2004
  • - Lee JJ, Kook H, Park MS, Nam JH, Choi BH, Song WH, Kim YK, Park KS, Lee IK, Chung IJ, Hwang TJ, Kim HJ: Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. Journal of Clinical Apheresis 19(2): 66-70, 2004
  • - Lee JJ, Kim HJ, Kim YJ, Lee S, Hwang JY, Lim YL, Kim DW: Imatinib mesylate induces a cytogenetic response in blast-crisis or interferon-failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcript. Leukemia 18(9): 1539-1540, 2004
  • - Takei M, Tachikawa E, Hasegawa H, Lee JJ: Dendritic cells maturation promoted by M1 and M4, end products of steroidal ginseng saponins metabolized in digestive tracts, drive a potent Th1 polarization. Biochemical Pharmacology 68(3):441-452, 2004.
  • [2003]
  • - Lee JJ, Nam CE, Kook H, Maciejewski J-P, Kim YK, Chung IJ, Park KS, Lee IK, Hwang TJ, Kim HJ: The constitution and telomere dynamics of bone marrow stromal cells in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant, 32(9):947-952, 2003
  • - Lee JJ, Nam CE, Cho SH, Park KS, Chung IJ, Kim HJ: Telomere length shortening in malignant lymphoma patients undergoing chemotherapy. Annals of Hematology, 82(8): 492-495, 2003
  • - Lee JJ, Chung IJ, Park KS, Cho SH, Cho D, Ryang DW, Park MR, Kim HJ: CD34 expression is associated with a poor clinical outcome in patients with acute promyelocytic leukemia. American Journal of Hematology 74(3):149-153, 2003
  • [2002]
  • - Lee JJ, Takei M, Hori S, Inoue Y, Harada Y, Tanosaki R, Kanda Y, Kami M, Makimoto A, Mineishi S, Kawai H, Heike Y, Ikarashi Y, Wakasugi H, Takaue Y, Hwang TJ, Kim HJ, Kakizoe T: The Role of PGE2 in the differentiation of dendritic cells: how do dendritic cells influence T cell polarization and chemokine receptor expression ? Stem Cell 20:448-459, 2002
  • - Lee JJ, Chung IJ, Shin DH, Cho SH, Cho D, Ryang DW, Khan AS, Kim HJ: Hemorrhagic fever with renal syndrome presenting with hemophagocytic lymphohistiocytosis. Emerging Infectious Diseases 8(2): 209-210, 2002
  • - Lee JJ, Chung IJ, Yang DH, Cho SH, Cho D, Ryang DW, Kim HJ: Clinical significance of CD56 expression in patients with acute myeloid leukemia. Leukemia & Lymphoma 43(9): 1897-1899, 2002
  • [2001]
  • - Lee JJ, Kook H, Chung IJ, Na JA, Park MR, Hwang TJ, Kwak JY, Sohn SK, Kim HJ: Telomere length changes in patient with aplastic anemia. British Journal of Haematology, 112(4): 1025-1030, 2001
  • - Lee JJ, Chung IJ, Park MR, Kook H, Hwang TJ, Ryang DW, Kim HJ: Clinical Efficacy of Granulocyte Transfusion Therapies in Patients with Neutropenia-Related Infections. Leukemia, 15(2): 203-207, 2001
  • - Lee JJ, Kim HJ, Chung IJ, Park MR, Ryang DW, Choi C: Secondary myeloid/natural killer cell acute leukemia following T-cell lymphoma. Leukemia & Lymphoma, 41(3-4): 457-460, 2001
  • - Lee JJ, Chung IJ, Park MR, Ryang DW, Park CS, Kim HJ. Increased angiogenesis and Fas-ligand expressions are independent processes in acute myeloid leukemia. Leukemia Research 25(12): 1067-1073, 2001
  • [2000]
  • - Lee JJ, Kim HJ, Chung IJ, Kook H, Park MR, Shin DH, Hwang TJ: Ruptured Klebsiella pneumoniae liver abscess after high-dose cyclophosphamide for severe aplastic anemia. American Journal of Hematology, 64(3): 218-220, 2000
  • - Lee JJ, Chung IJ, Ahn YK, Park MR, Shin DH, Cho JG, Kim HJ: Life-threatening paroxysmal supraventricular tachycardia developed during granulocyte transfusion therapy for neutropenia related infection. Leukemia, 14(7): 1324-1325, 2000
  • [1999]
  • - Lee JJ, Kim HJ, Chung IJ, Kim JS, Sohn SK, Kim BS, Lee KH, Kwak JY, Park YH, Ahn JS, Park YS. Comparisons of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study. Leukemia Research 23(5): 425-432, 1999
  • - Lee JJ, Kook H, Chung IJ, Kim HJ, Park MR, Kim CC, Nah JH, Hwang TJ. Telomere Length Changes in Patients Undergoing Hematopoietic Stem Cell Transplantation. Bone Marrow Transplant 24(4): 411-415, 1999
  • - Lee JJ, Kim HJ, Chung IJ, Park MR, Seo KS, Jeong YY, Kim JK. Portal, mesenteric, and splenic vein thromboses after splenectomy in a patient with chronic myeloid leukemia variant with thrombocythemic onset. American Journal of Hematology 61(3): 212-215, 1999
  • <저서>
  • 혈액학(2011)
  • Multiple Myeloma an Overview(2012)
  • Multiple Myeloma a Quick Reflection on the Fast Progress(2013)

학회활동

  • 1989-: 대한의사협회 회원
  • 1997-: 대한내과학회 회원
  • 1997-: 대한혈액학회 회원
  • 1997-: 대한암학회 회원
  • 1998-: 대한조혈모세포이식학회 회원
  • 2001-: 대한면역학회 회원
  • 2001-: ISEH 회원
  • 2002-: 미국혈액학회(ASH) 회원
  • 2008.1-현재: 대한혈액학회 다발성골수종연구회 운영위원
  • 2008.1-현재: 대한혈액학회 림프종연구회 운영위원
  • 2009.5-현재: 대한면역학회 면역치료연구회 운영위원

보도자료

  • 화순전남대병원 ‘난치성 혈액암’ 치료 길 열었다(광주일보 2013/10/28)
  • 화순전남대병원 혈액암 다발골수종 치료제 개발(뉴시스 2013/10/27)
  • 화순전남대병원, '항암 면역치료제' 국내 첫 개발 (아시아경제 2013/10/27)
  • 환자의 면역력 높여 암 세포 죽인다 (전남일보 2010/10/27)
전남대학교 의과대학(대학원 BMSGP) 주소 : 58128)전라남도 화순군 화순읍 서양로 264 전남대학교 의과대학 융합연구동(M2) 104호
전화 : 061-379-2541(대학원행정실) 이메일 : A5012@jnu.ac.kr
Copyright © 전남대학교 대학원 BMSGP ALL RIGHTS RESERVED. DESIGN BY RIBROSOFT